APOL1 Gene and Polymorphism

Pathophysiology

APOL1 protein toxicity mechanism: 1. Increased intraglomerular pressure: APOL1 risk variants → altered podocyte function → ↑ glomerular hyperfiltration 2. Oxidative stress: Mitochondrial dysfunction; ↑ ROS generation 3. Autophagy dysregulation: Impaired cellular waste removal 4. Inflammatory cascade: Pro-inflammatory cytokine activation 5. Podocyte injury: Cell death, foot process effacement, proteinuria 6. Glomerular sclerosis: Progressive fibrosis

APOL1-Associated Glomerular Disease Phenotypes

Screening and Risk Assessment

APOL1 Testing Indications: 1. Black/African American patients with: - FSGS or collapsing glomerulopathy - CKD of unclear etiology - Proteinuric kidney disease (to refine diagnosis) - Family history of ESRD

2. Clinical utility:
   • Two risk alleles: Heightened surveillance; aggressive BP/proteinuria management
   • One risk allele: Baseline risk similar to general population; lifestyle modifications
   • G0/G0 genotype: Reassuring (low genetic risk)

Testing limitations: - APOL1 presence does NOT diagnose disease (many carriers remain healthy) - Environmental/behavioral factors (HTN, proteinuria, smoking, diet) modulate expression - Test results should inform but NOT replace clinical judgment

Management of APOL1-Associated CKD

1. Blood Pressure Control: - Target: <120 systolic per SPRINT-CKD (intensive control beneficial) - Agents: ACEi/ARB preferred (↓ proteinuria + BP control) - Monitoring: Monthly BP; adjust medications for target

2. Proteinuria Reduction: - Goal: <0.3 g/day (complete remission) or ↓ >50% from baseline - First-line: ACEi or ARB (if not contraindicated) - Addition: SGLT2 inhibitor (dapagliflozin, empagliflozin) for synergistic effect - Consider: Finerenone (non-steroidal MRA) if eGFR >25 and K⁺ <5.5

3. Immunosuppression (FSGS/Collapsing): - Steroid-resistant FSGS: Often responds poorly to corticosteroids alone - Consider rituximab or calcineurin inhibitor (tacrolimus, cyclosporine) if biopsy-proven FSGS - Evidence base: Limited; outcomes variable - Referral: Nephrology for biopsy-proven disease + specialist management

4. Lifestyle modifications: - Weight loss: If overweight/obese (↓ proteinuria) - Sodium restriction: <3 g/day - Smoking cessation: Improves renal outcomes - DASH diet: Cardiovascular + renal protection

5. Monitoring: - Renal function: Baseline, then every 3–6 months - Proteinuria: 24-hr urine or uACR at baseline, then every 3–6 months (target <0.3 g/day) - BP: Home monitoring; goal <120 systolic - Medication adherence: Critical; pill counts, pharmacy refills

Prognosis

With two APOL1-risk alleles: - Hypertensive variants: Progressive but slower (10–20 years to ESRD if managed well) - FSGS/Collapsing: More aggressive (2–5 years to ESRD if resistant to therapy) - Modifiable risk factors: HTN control, proteinuria reduction, smoking cessation ↑ renal survival

Pathophysiology

Sickle hemoglobin (HbS) polymerization: 1. Low O₂ tension → HbS polymerization → rigid RBC 2. Hemolysis: Shortened RBC life span (10–20 days vs. normal 120 days) 3. Renal vasculature involvement: - Medullary hypoxia: ↓ O₂ in renal medulla (countercurrent multiplier concentrates HbS) - Vaso-occlusion: Sickled RBCs lodge in medullary vessels - Hemolysis in kidney: Local tissue damage, inflammation

Result: Progressive glomerulonephritis + medullary necrosis + papillary dysfunction

Clinical Manifestations

Specific Complications

Renal Failure in Sickle Cell Disease

Incidence: ~3–4% reach ESRD by age 50 (vs. <1% general population)

Mechanisms leading to ESRD: 1. Progressive FSGS from hyperfiltration (most common) 2. Sickle cell glomerulonephritis (immune complex glomerulonephritis; rare) 3. Acute tubular necrosis (ATN) from sickle crises (vaso-occlusion, rhabdomyolysis) 4. Chronic vascular disease (atherosclerosis; multifactorial)

Risk factors for progression: - Male gender (more aggressive course) - Sickle cell disease SS (worse than sickle cell trait AS or SC disease) - Baseline proteinuria (nephrotic-range proteinuria = ↑ risk) - Hypertension (common complicating factor) - Frequent sickle crises (recurrent ischemia)

Management of Sickle Cell Nephropathy

1. Renal-Protective Therapy: - ACEi/ARB: Indicated if proteinuria present (↓ proteinuria ~40%) - Caution: Some sickle cell patients on ACEi report fewer crises (anecdotal benefit of vasodilation) - Monitoring: K⁺, Cr (risk hyperkalemia + AKI if dehydrated) - SGLT2i: Consider if proteinuric (dapagliflozin, empagliflozin)

2. Blood Pressure Control: - Target: <130/80 (KDIGO recommendation; intensive control beneficial) - Agents: ACEi/ARB preferred; CCB acceptable

3. Sickle-Specific Management: - Hydroxyurea: ↓ HbS polymerization; ↓ hemolysis + RBC sickling - Effect: ↑ HbF (fetal hemoglobin; doesn’t polymerize), ↓ hemolysis - Renal benefit: Indirect benefit via ↓ hemolysis - Voxelotor: ↑ RBC oxygen affinity; ↓ polymerization - Emerging: Possible renal protection (under investigation) - Gene therapy, stem cell transplant: Curative but high risk/availability limited

4. Polyuria Management: - Hydration: Emphasize water intake (min 2–3 L/day) - NSAIDs: Absolutely contraindicated - Electrolytes: Monitor Na⁺, K⁺, Ca²⁺ for imbalance - Fluid during crises: IV hydration essential during vaso-occlusive crises

5. Monitoring: - Renal function: Baseline, then annually (or more frequent if CKD present) - Proteinuria: Baseline, then annually (target <0.3 g/day) - BP: Home monitoring; goal <130/80 - Hemoglobin/reticulocytes: Monitor for adequacy of RBC production

Prognosis

• Mild renal disease: Many remain stable with proteinuria <1 g/day for years
• Nephrotic proteinuria: Progressive; many reach ESRD in 5–10 years if untreated
• Median age to ESRD (untreated): ~40 years (vs. >80 years in general CKD population)
• Dialysis outcomes: Sickle cell ESRD patients have worse survival on dialysis (↑ infections, cardiovascular events)
• Transplantation: Improved outcomes; equivalent allograft survival to non-sickle cell ESRD recipients

Epidemiology

Incidence: 2–10% of HIV-infected patients (varies by region, comorbidities)

Risk factors: - Low CD4 count (<200 cells/μL; highest risk) - Black/African descent (3–5× higher incidence; APOL1-related) - Hepatitis C coinfection - IV drug use - Diabetes, hypertension

Histologic Classification

Clinical Presentation

HIVAN (most common; 80% of HIVKAN): - Nephrotic proteinuria: >10 g/day (often!) - Preserved renal function early: eGFR may be normal initially - AKI possible: Rapid Cr rise to ESRD (weeks–months if untreated) - Hypertension: Variable; not always prominent - Urinalysis: Proteinuria >3+ on dipstick; minimal hematuria/RBC casts

FSGS (less aggressive): - Proteinuria: 1–5 g/day (less than HIVAN) - More gradual decline: eGFR ↓ over months

Diagnosis

Clinical suspicion: - HIV+ patient with proteinuria (often in setting of low CD4) - Rapid progression to ESRD (high clinical likelihood of HIVAN) - Preserved renal function with heavy proteinuria (distinctive of HIVAN)

Biopsy (definitive): - Indicated if diagnosis uncertain (differentiate HIVAN from immune complex GN, secondary causes) - Light microscopy: Collapsing GN, tubular dilation - EM: HIV particles in podocytes (electron microscopy; research only) - IF: Negative to minimal immune complexes (distinguishes from ICGN)

Management

1. Antiretroviral Therapy (ART) — FOUNDATION: - Most critical intervention: Immune reconstitution dramatically improves renal outcomes - Mechanism: ↓ HIV replication → podocyte recovery from infected state - Proteinuria response: Often ↓ proteinuria 50–80% with immune reconstitution - Timing: Start ART immediately if low CD4 + proteinuria - Expected timeline: Proteinuria may take weeks–months to improve; Cr stabilization possible even if initially rising

2. Immunosuppression (Adjunctive): - ACEi/ARB: First-line for proteinuria reduction (synergistic with ART) - Expected benefit: ↓ Proteinuria 40–50% (additional to ART benefit) - Caution: Monitor K⁺, Cr (hyperkalemia, AKI risk) - Corticosteroids: Controversial; may be adjunctive in severe HIVAN - Mechanism: Anti-inflammatory, ↓ immune activation - Dose: Prednisolone 0.5–1 mg/kg/day × 4–6 weeks, then taper (evidence limited) - Caution: Infection risk with steroids + severe immunosuppression (CD4 <50) - Evidence: Limited RCT data; observational studies suggest possible benefit if CD4 >200 - Cyclosporine (CNI): Reports of benefit in HIVAN (rare use); mechanism unclear - Evidence: Anecdotal; not standard - Risk: Nephrotoxicity (risk despite already reduced renal function)

3. Blood Pressure Control: - ACEi/ARB preferred (proteinuria reduction + BP control dual benefit) - Target: <120 systolic (per SPRINT-CKD)

4. Renal Replacement Therapy: - Hemodialysis/peritoneal dialysis: If ESRD develops - Outcomes: Possible; survival on dialysis ↓ vs. non-HIV ESRD (↑ infections, opportunistic infections, poor compliance) - Transplantation: Possible with undetectable VL + adequate CD4; outcomes improving

Response to Therapy and Prognosis

Pre-ART era (1980s–1990s): - Rapid progression: 50% ESRD within 1–2 years of diagnosis - Poor dialysis outcomes: High mortality

With modern ART: - Dramatic improvement: CD4 recovery → podocyte repair → proteinuria ↓ - Renal recovery: Some achieve normal eGFR despite initial ESRD trajectory - Prognosis: If Cr <2 mg/dL and CD4 recovers >200, ~70% achieve complete remission - Key: Early ART initiation at time of HIVAN diagnosis critical

Mechanism and Pathophysiology

Obesity-induced renal changes: 1. Glomerular hyperfiltration: ↑ GFR (initially) - Hemodynamic driver: Obesity → ↑ systemic and glomerular hydrostatic pressure - Adipokine effect: Leptin ↑ (activates RAAS, ↑ sympathetic tone) 2. Podocyte stress: ↑ filtration pressure + metabolic stress (lipotoxicity) 3. Proteinuria development: Foot process effacement 4. Glomerulosclerosis: Progressive fibrosis → CKD 5. Tubular dysfunction: Salt reabsorption abnormalities

Associated metabolic changes: - Insulin resistance: ↑ hyperinsulinemia → renal retention of sodium + volume expansion - Dyslipidemia: Lipid accumulation in glomerulus → oxidative stress - Hypertension: Obesity-related HTN (renin system activation) - Inflammation: Adipose tissue produces inflammatory cytokines (TNF-α, IL-6)

Clinical Presentation

Early phase (obesity with preserved GFR): - Proteinuria: Mild (0.3–1 g/day) - Preserved eGFR: Often normal or even ↑ (hyperfiltration) - Hypertension: Common (~50%) - Metabolic syndrome: Often present (HTN, dyslipidemia, impaired glucose tolerance)

Progressive phase: - ↑ Proteinuria: May reach nephrotic range - eGFR decline: Begins slowly; progressive in some - Hypertension: Worsens

Histology (if biopsied): - Light microscopy: Glomerulomegaly (enlarged glomeruli), FSGS pattern (segmental sclerosis) - “Obesity-related glomerulopathy” pattern (not a specific diagnosis; descriptive) - Podocyte enlargement: Common finding - Immune deposition: Usually absent (distinguishes from primary FSGS)

Diagnosis

Clinical context: - BMI >30 kg/m² (obesity; BMI 30–35 = overweight/Class I obesity; >35 = Class II-III) - Proteinuria: Often asymptomatic (discovered on screening) - Preserved renal function early: Diagnostic clue vs. primary FSGS - Absence of systemic disease: (nega serologies, normal complement) - Kidney biopsy: Not routinely needed; diagnosis often clinical

Management: Weight Loss as Primary Therapy

1. Weight Loss (Most Important): - Target: 5–10% body weight loss (feasible; associated with proteinuria ↓) - Greater loss: 15–20% weight loss → profound proteinuria reduction (~50%) - Mechanisms: - ↓ Glomerular filtration pressure (hemodynamic) - ↓ Inflammatory cytokines - ↓ Insulin resistance - Restored podocyte function (possible) - Timeline: Proteinuria reduction expected over weeks–months

Methods: - Lifestyle: Caloric restriction (500–1000 kcal/day deficit), physical activity (150 min/week), dietary counseling - Pharmacotherapy: GLP-1 agonists (semaglutide, tirzepatide), phentermine (short-term) - Emerging data: Semaglutide + lifestyle → weight loss >10%; renal benefit being studied - Bariatric surgery: Gastric bypass, sleeve gastrectomy - Effect: 30–50% weight loss; proteinuria often resolves - Indication: BMI >40 or BMI 35–39 with comorbidities (diabetes, HTN, CKD)

2. Pharmacologic Renal Protection: - ACEi/ARB: First-line for proteinuria reduction (independent of weight loss) - Effect: ↓ Proteinuria 20–40% - Synergistic with weight loss - SGLT2 inhibitor: Emerging role - Weight loss: SGLT2i cause 2–3 kg weight loss (glycosuria) - Proteinuria reduction: Additional 20–40% beyond ACEi - GLP-1 agonist: Semaglutide - Weight loss: 5–15% body weight (dose-dependent) - Renal outcomes: Improved in SUSTAIN-6 (↓ ESRD, albuminuria)

3. Blood Pressure Control: - Target: <120 systolic (SPRINT-CKD) - Agents: ACEi/ARB preferred (dual benefit: BP + proteinuria)

4. Metabolic Control: - Diabetes: Tight glucose control (HbA1c <7% if tolerable without hypoglycemia) - Agents: Metformin, SGLT2i, GLP-1 agonist - Dyslipidemia: Statin therapy (even in non-diabetics with CKD + obesity; cardiovascular benefit) - Hypertension: Target <120/70

5. Monitoring: - Proteinuria: Baseline, then at 3 months (assess response to weight loss), then every 6 months - Renal function: Baseline, then annually (or more if CKD present) - BP: Home monitoring

Prognosis

• With weight loss + ACEi/ARB: Many stabilize; some achieve near-normal eGFR + resolved proteinuria
• Without intervention: Progressive CKD (eGFR ↓ ~1–3 mL/min/year)
• Bariatric surgery outcomes: 50–70% achieve complete proteinuria remission

Physiologic Changes in Pregnancy

Preexisting CKD in Pregnancy

Preeclampsia and AKI in Pregnancy

SARS-CoV-2 Infection: Acute and Chronic Renal Manifestations

Vaccination and Kidney Disease

SARS-CoV-2 vaccines and AKI: - No direct association between vaccination and AKI (extensive post-market surveillance) - Coincidental AKI: Reported in vaccinated patients but temporal relationship likely coincidental - Immune-mediated GN: Rare case reports of post-vaccine nephritis; causal link unproven

Recommendation: COVID-19 vaccination recommended for ALL patients including those with CKD (prevent severe COVID-19 + AKI risk)

Scenario 1: APOL1 Risk Alleles with Proteinuria

Clinical: 42-year-old Black male with hypertension (BP 158/96 on amlodipine), eGFR 52, uACR 350 mg/g (overt albuminuria). APOL1 testing reveals G1/G2 (two risk alleles).

Plan: 1. Start ACEi/ARB: Lisinopril 10 mg daily (renal protection + BP control) - Goal: ↓ Proteinuria 30–50%; target uACR <30 mg/g - Monitor: Cr 1 week (expect stable or slight ↑ 10–30%), K⁺ 1 week, then q3 months 2. Tighten BP control: Increase amlodipine to 10 mg daily; target BP <120 systolic - Goal: <120/80 (SPRINT-CKD benefit) 3. Lifestyle: Weight loss if overweight, sodium <3 g/day, DASH diet, smoking cessation 4. SGLT2i: Consider dapagliflozin 10 mg daily (additional proteinuria ↓ + CKD progression ↓) 5. Monitoring: - 3 months: Recheck uACR (goal ↓ >50% from baseline 350) - 6 months: Assess BP control, Cr, K⁺, proteinuria - Genetic counseling: Discuss APOL1 risk to family members (siblings, children); screening consideration 6. Expected outcome: With RAAS inhibition + lifestyle, many achieve proteinuria ↓ and slow CKD progression

Scenario 2: Sickle Cell Disease with Proteinuria

Clinical: 36-year-old male with sickle cell disease SS, multiple prior sickle crises, BP 148/92, eGFR 55, urine dipstick 2+ proteinuria (24-hr urine 2.8 g).

Plan: 1. Start ACEi/ARB: Losartan 50 mg daily (proteinuria reduction; possible crisis benefit via vasodilation) - Monitor: Cr at 1 week (expect stable ±10%), K⁺ 1 week then q3 months - Note: Some evidence ACEi reduces vaso-occlusive crisis frequency (anecdotal); possible added benefit 2. Target BP: <130 systolic (add CCB if needed; amlodipine safe) 3. Sickle-specific: - Hydroxyurea: If not already on; ↓ HbS polymerization, hemolysis (indirect renal benefit) - Hydration: Educate on adequate fluid intake (polyuria from concentrating defect; risk of dehydration) 4. Avoid NSAIDs: Acetaminophen for pain (↓ AKI risk) 5. Hyperuricemia management: - Serum uric acid: Check baseline (expect ↑ from hemolysis) - If >8 mg/dL and/or prior gout: Start allopurinol 300 mg daily - Maintain hydration: ↓ Uric acid concentration 6. Monitoring: - Renal function: Baseline, then 3 months, 6 months, then annually - Proteinuria: Goal ↓ to <1 g/day (nephrology referral if nephrotic range develops) - Hematuria: Monitor; self-limited usually; no intervention unless massive (rare) 7. Expected: With ACEi + hydration + pain control, many stabilize; slow CKD progression vs. untreated

Scenario 3: Preeclampsia at 28 Weeks

Clinical: 32-year-old primigravida at 28 weeks gestation presents with BP 158/102 (baseline 115/70), proteinuria 4+ on dipstick (24-hr urine 2.8 g), headache, visual changes. Labs: platelets 85,000, AST 120, Cr 1.3 (baseline 0.8).

Diagnosis: Severe preeclampsia (HTN ≥160/110 + proteinuria + maternal organ dysfunction: thrombocytopenia, hepatitis, AKI)

Plan (hospitalization required): 1. Delivery consideration: At 28 weeks (borderline periviability; neonatology consult) - If deliver: Corticosteroids for fetal lung maturity, magnesium sulfate for seizure prophylaxis - If expectant management: Hospitalization, antihypertensives, close monitoring (28–34 weeks more favorable) 2. Magnesium sulfate: 4 g IV load over 30 min, then 1–2 g/hr (seizure prophylaxis) 3. Antihypertensives: - Goal BP: 140–150 systolic (not <120; goal prevent stroke without compromising placental perfusion) - Agent: Labetalol 20 mg IV, repeat q10 min (max 80 mg in 10 min interval); then consider oral (methyldopa 500 mg TID or labetalol 400–800 mg BID) - Avoid: ACEi/ARB (teratogenic 2nd–3rd trimester), NSAIDs (oligohydramnios, fetal renal dysfunction risk) 4. Fluid management: IV fluids cautiously (risk oliguria from intravascular depletion despite edema) - Oliguria: Monitor UO; modest hydration trial if UO <0.5 mL/kg/hr - Avoid aggressive diuresis: Worsens renal function 5. Monitor closely: Daily Cr, K⁺, Mg²⁺, platelets, liver enzymes, urine output; fetal monitoring (NST, biophysical profile) 6. RRT if: ↑ K⁺ (>6.0), severe acidosis, fluid overload with pulmonary edema 7. Postpartum: Expectation = BP, Cr normalize 3–6 weeks; follow-up renal function at 6 weeks (rule out permanent kidney injury)

Question 1

A 35-year-old Black female with two APOL1-risk alleles presents with nephrotic proteinuria (uACR 420 mg/g), BP 142/88, eGFR 65, and normal serum complement. Kidney biopsy shows collapsing FSGS. Which of the following is MOST appropriate?

1. Steroid therapy alone (1 mg/kg/day prednisone)
2. ACEi/ARB monotherapy without additional immunosuppression
3. ACEi/ARB + weight loss intervention + close proteinuria monitoring
4. Immediately initiate rituximab + cyclophosphamide
5. Genetic counseling only; observe without therapy

Answer: C (ACEi/ARB monotherapy first-line with lifestyle modification; immunosuppression reserved if resistant)

Rationale: - APOL1-associated FSGS: Often steroid-resistant; ACEi/ARB ↓ proteinuria (renal hemodynamic effect) in 40–50% - Weight loss: If overweight, ↓ proteinuria (↓ glomerular hyperfiltration) - Monitor response: 3 months of ACEi/ARB + lifestyle; if proteinuria ↓ >50%, continue - Reserve immunosuppression: If ACEi/ARB + lifestyle fails (persistent nephrotic proteinuria), consider rituximab or CNI (evidence limited; specialist decision) - Steroid monotherapy: Ineffective in APOL1-related FSGS (steroid-resistant phenotype) - Genetic counseling: YES—family screening for APOL1 (siblings, children); risk stratification

Question 2

A 24-year-old female with sickle cell disease SS presents with gross hematuria (dark red urine), flank pain, polyuria (8 L/day documented), and BP 148/96. Cr 1.2, eGFR 58, uACR 280 mg/g. Urinalysis shows RBCs, possible RBC casts. Which diagnosis is MOST likely?

1. Lupus nephritis (Class IV)
2. IgA nephropathy
3. Sickle cell nephropathy with hematuria from papillary necrosis
4. ANCA-associated vasculitis (GPA)
5. Diabetic nephropathy

Answer: C (sickle cell nephropathy; polyuria + hematuria + preserv renal function)

Rationale: - Sickle cell disease = definitive diagnosis — informs pathophysiology - Polyuria (8 L/day): Classic for sickle cell medullary damage (concentrating defect) - Gross hematuria + flank pain: Suggests papillary necrosis sloughing necrotic tissue into collecting system - Preserved eGFR (58): Sickle nephropathy early hyperfiltration phase - Mild proteinuria (uACR 280): Consistent with early sickle glomerulosclerosis - Hypertension: Common in sickle cell CKD - Management: Hydration, pain control (acetaminophen not NSAIDs), monitor for obstruction; ACEi for proteinuria ↓ - Lupus would have ANA+, complement ↓, anti-dsDNA; not in sickle disease - IgA would have biopsy showing IgA deposits; presentation less consistent - ANCA would have systemic symptoms, elevated ANCA serology, systemic vasculitis

Question 3

A 30-year-old primigravida at 24 weeks gestation with preexisting CKD (eGFR 35, uACR 180 mg/g) on lisinopril + amlodipine, BP controlled 128/82, presents with new BP 156/98, urine dipstick 3+ protein, headache. Labs: platelets 120,000 (baseline unknown), AST 95. Which is MOST important next step?

1. Continue lisinopril; add hydralazine for BP control
2. Admit for delivery (24 weeks contraindicated for continuation)
3. Start magnesium sulfate; admit for observation; assess for preeclampsia vs. CKD progression
4. Increase lisinopril to 20 mg daily
5. Administer betamethasone and plan delivery immediately

Answer: C (admit for magnesium sulfate + monitoring; distinguish preeclampsia from CKD progression)

Rationale: - New hypertension + new proteinuria rise + thrombocytopenia + transaminitis = preeclampsia features - STOP lisinopril immediately (ACEi teratogenic 2nd–3rd trimester; causes renal dysgenesis, oligohydramnios) - Magnesium sulfate: Essential (seizure prophylaxis for preeclampsia) - Admit for monitoring: 24 weeks borderline viability; need careful assessment - If confirms severe preeclampsia → delivery urgently recommended (maternal-fetal risk balance) - If CKD progression without preeclampsia → can continue pregnancy with close observation - Distinguish preeclampsia from CKD progression: - Preeclampsia findings: New HTN post-20 weeks + NEW proteinuria rise + thrombocytopenia + visual/neuro symptoms → DELIVERY - CKD only: Known CKD, stable proteinuria (relative to baseline), no systemic symptoms → continue pregnancy with monitoring - This patient: Likely preeclampsia (new HTN + rising proteinuria + low platelets + hepatitis) superimposed on CKD - Delivery timing: If confirms preeclampsia, deliver urgently (risks outweigh prematurity)